

An Active Immune Defence with a Minimal CRISPR (clustered regularly interspaced short  
palindromic repeats) RNA and Without the Cas6 Protein

Lisa-Katharina Maier<sup>1,4</sup>, Aris-Edda Stachler<sup>1,4</sup>, Sita J. Saunders<sup>2</sup>, Rolf Backofen<sup>2,3</sup> and Anita  
Marchfelder<sup>1</sup>

<sup>1</sup> From the department of Biology II, Ulm University, 89069 Ulm, Germany

<sup>2</sup> Bioinformatics Group, Department of Computer Science, University of Freiburg, Georges-Köhler-  
Allee 106, 79110, Freiburg, Germany

<sup>3</sup> Centre for Biological Signalling Studies (BIOSS), Cluster of Excellence, University of Freiburg,  
Germany

<sup>4</sup> These authors contributed equally.

\*Running title: Prokaryotic Immune Defence With an icrRNA and Without Cas6

To whom correspondence should be addressed: Anita Marchfelder, Biology II, Ulm University, 89069  
Ulm, Germany, phone: +49-731-5022658, Fax: +49-731-50-12-22658, E-mail:  
anita.marchfelder@uni-ulm.de

This work was supported by the German Research Council (Deutsche Forschungsgemeinschaft),  
through the research group FOR 1680 "Unravelling the prokaryotic immune system" (grant DFG  
MA1538/17-1 and BA2168/5-1).

**Keywords:** CRISPR-Cas, type I-B, *Haloferax volcanii*, Archaea, Cas6, crRNA

**Background:** CRISPR RNAs (crRNAs) are  
generated by Cas6b in type I-B systems. They  
are essential for the interference reaction.

**Results:** An icrRNA is generated independently  
from Cas6b and functions like a crRNA.

**Conclusion:** In the presence of an icrRNA  
Cas6b is not required for the interference  
reaction.

**Significance:** This set up allows the Cas6b  
independent generation of icrRNAs and  
therewith an interference without Cas6b.

## ABSTRACT

The prokaryotic immune system CRISPR-  
Cas<sup>1</sup> is a defence system that protects  
prokaryotes against foreign DNA. The short  
CRISPR RNAs (crRNAs) are central  
components of this immune system. In  
CRISPR-Cas systems type I and III crRNAs  
are generated by the endonuclease Cas6. We  
developed a Cas6b<sup>2</sup>-independent crRNA  
maturation pathway for the *Haloferax* type  
I-B system *in vivo*, that expresses a  
functional crRNA that we termed  
independently generated crRNA (icrRNA).  
The icrRNA is effective in triggering  
degradation of an invader plasmid carrying  
the matching protospacer sequence. The

**Cas6b-independent maturation of the  
icrRNA allowed mutation of the repeat  
sequence without interfering with signals  
important for Cas6b processing. We  
generated 23 variants of the icrRNA and  
analysed them for activity in the interference  
reaction. icrRNAs with deletions or  
mutations of the 3' handle are still active in  
triggering a interference reaction. The  
complete 3' handle could be removed  
without loss of activity. However  
manipulations of the 5' handle mostly led to  
loss of interference activity. Furthermore we  
could show that in the presence of an  
icrRNA a strain without Cas6b ( $\Delta cas6b$ ) is  
still active in interference.**

Prokaryotes defend themselves against invaders  
using several different mechanisms to degrade  
foreign DNA or RNA, one of which is the  
CRISPR-Cas system (1-6). This defence  
mechanism progresses in three steps: (1)  
adaptation, (2) CRISPR RNA expression and  
processing and (3) invader degradation. During  
the first step, the cell identifies a new invader  
and integrates a piece of the invader DNA  
(termed protospacer) into the CRISPR locus of  
the host (as soon as the protospacer has been  
integrated into the CRISPR locus, it is termed

spacer). An important distinguishing characteristic for the selection of a protospacer in the type I and type II CRISPR-Cas systems, is the protospacer adjacent motif (PAM) (7,8). This motif is located in the invader DNA, directly adjacent to the protospacer. The PAM sequence is important, not only for its selection as a spacer but also for the third step of the process, the interference reaction. In the second step of the defence the CRISPR RNA is synthesized yielding a long pre-crRNA that is processed into the mature functional crRNAs. These short RNAs are essential for the last step, the interference, where they detect the invader sequence and trigger degradation of the invader by Cas proteins (2,9).

The prokaryotic immune system comes in a variety of different types that all carry out the same reaction namely the defence against foreign DNA or RNA. Data about the different systems reported show, that although they carry out the same reaction they clearly differ in various aspects of the pathway. The different types of CRISPR-Cas have been grouped on the basis of their various Cas proteins into three major classes: CRISPR-Cas type I, II and III (7), that have been further divided into initially ten subclasses (IA-F; IIA-B; IIIA-B) (7), with the number of newly defined subclasses constantly rising as more data about the systems are reported (10,11).

The key element in all CRISPR-Cas defence systems is the crRNA. The biogenesis of the crRNA involves either two or three steps, depending on the system: in all cases the first step is the transcription of the CRISPR RNA locus into a long precursor, the pre-crRNA. The following maturation of the crRNA is catalysed by the Cas6 protein in CRISPR-Cas type I and type III systems. In some type I systems Cas6 is part of the CRISPR associated complex of antiviral defence (Cascade) (12), that consists of different Cas proteins depending on the subtype (2). In contrast in type III system Cas6 is a standalone endonuclease (13,14). Processing by Cas6 within the repeat sequence directly yields the mature functional crRNA in types I-A, I-E and I-F (9). The resulting crRNA consists of an 8 nucleotide repeat derived 5' handle, the invader-targeting spacer sequence and the 3' handle, that contains the remainder of the repeat sequence (Figure 1A) (2). In some type I systems (I-E and I-F) the Cas6 proteins stays bound to the crRNA after processing. In type III systems a second maturation step is observed after Cas6 processing, that shortens

the crRNA 3' end and sometimes removes the complete repeat sequence downstream of the spacer (14,15).

The initial invader DNA recognition is governed by Watson-Crick base pairing with a 7–10 nt segment of the crRNA referred to as the 'seed' sequence (16–19). The seed sequence is involved in initial pairing between crRNA and invader, and allows rapid probing of different regions of cellular nucleic acids. If a perfect match between seed sequence and target DNA is found the remainder of the spacer sequence of the crRNA base pairs with the invader DNA. In the type I-E system the seed sequence is a seven nucleotide long non contiguous sequence between the 5' end of the crRNA-spacer sequence and the invader (17). In the type I-B system this seed sequence is with 10 nucleotides slightly longer (20). An additional prerequisite for the interference is the presence of the PAM sequence in the invader DNA (2).

Here we investigate the function of Cas6 in the interference reaction and the essential requirements for the crRNA in the type I-B system of the archaeon *Haloferax volcanii*. *H. volcanii* contains only one CRISPR-Cas system (I-B), that consists of eight Cas proteins (Cas1-Cas5, Cas6b, Cas7 and Cas8b) and three CRISPR RNA arrays (20). We could previously identify the PAM sequences for this system showing that six different PAMs are active in triggering degradation (21). The *Haloferax* I-B system has a Cascade like complex, with Cas6b copurifying with the Cas5 and Cas7 proteins and the crRNA (22). It has been shown that the Cas6b protein is involved in crRNA maturation and that the crRNA 5' handles are eight nucleotides long, however different 3' length have been reported (22).

We developed here a Cas6b-independent crRNA maturation pathway for the *Haloferax* type I-B system *in vivo*, that expresses a functional crRNA that we termed independently generated crRNA (icrRNA). The icrRNA is transcribed with flanking tRNA-like structures (so-called t-elements) that are processed by the tRNA processing enzymes RNase P and tRNase Z (23). The icrRNA is effective in triggering degradation of an invader plasmid carrying the matching protospacer sequence.

We show here that a minimal crRNA in the I-B system needs a seven nucleotide 5' handle and does not require a 3' handle at all. In addition, we show that the Cas6b protein is not required for the interference reaction when an icrRNA is present.

With the Cas6b-independent maturation pathway developed here, the first *in vivo* analysis of crRNA characteristics essential for the interference reaction was possible.

## EXPERIMENTAL PROCEDURES

**Strains** - *H. volcanii* strains H119 (strains used are listed in Table 1),  $\Delta cas6$  ( $\Delta pyrE2$ ,  $\Delta leuB$ ,  $\Delta trpA$ ,  $\Delta cas6$ ) (22) and  $\Delta C$  ( $\Delta pyrE2$ ,  $\Delta leuB$ ,  $\Delta trpA$ ,  $\Delta C::trpA^+$ ) (this study) were grown aerobically at 45°C in Hv-YPC medium (21). *H. volcanii* strains  $\Delta cas6$  and  $\Delta C$  containing plasmids were grown in Hv-Ca or Hv-min medium with the appropriate supplements. *E. coli* strains DH5 $\alpha$  (Invitrogen) and GM121 (24) were grown aerobically at 37°C in 2YT medium (25).

**Construction of plasmids and transformation of *H. volcanii***- The plasmids for expressing icrRNA (pTA409-telecRNA, pTA232-telecRNA and telecRNA variants in both vectors) were generated as follows (plasmids are listed in Table 1). The DNA fragment containing the crRNA or crRNA mutants flanked by t-elements were ordered from GeneArt® as plasmids pMA-RQ-telecRNA, pMA-telecRNA. Plasmids contained a synthetic *Haloferax* promoter (Anice Sabag-Daigle and Charles J. Daniels, in preparation), the crRNA, flanked by t-elements and a synthetic *Haloferax* terminator (Anice Sabag-Daigle and Charles J. Daniels, in preparation). Plasmids were digested with KpnI and BamHI to isolate the DNA fragment containing the complete insert. The resulting fragment was cloned into pTA409 (26) and pTA232 (27) (both digested with KpnI and BamHI). Four crRNA mutants were generated by inverse PCR on pMA-telecRNA using primer pairs (primer sequences are listed in Table 1) itele1/dell, itele1/dell, itele1/dell and itele1/dell to generate variant 13 (deletion of the last five nucleotides of the 3' handle), 14 (deletion of the last ten nucleotides of the 3' handle), 15 (deletion of the last fifteen nucleotides of the 3' handle) and 16 (deletion of the last twenty nucleotides of the 3' handle), respectively. In preparation for transformation all plasmids were passaged through *E. coli* GM121 cells to avoid methylation. *Haloferax* cells were subsequently transformed using the polyethylene glycol method (27,28).

**Generation of a CRISPR locus C gene deletion strain ( $\Delta C$ )**- The deletion of the CRISPR locus C was achieved by using the pop-in/pop-out method as described previously

(24,25,29). The region upstream of the gene for CRISPR locus C was PCR amplified with flanking regions from the chromosomal DNA of *H. volcanii* strain H119 using primers Cdelup (containing the restriction site KpnI) and Cdelupi (containing the restriction site EcoRV). The resulting 300 base pair PCR fragment was subsequently cloned into the vector pTA131 (digested with KpnI and EcoRV), yielding pTA131-Cup. Next the region downstream of the locus C gene was amplified using primers Cdeldo (containing the restriction site XbaI) and Cdeldoi (containing the restriction site EcoRV). The resulting 500 bp fragment was cloned into the plasmid pTA131-Cup (digested with EcoRV and XbaI), yielding plasmid pTA131-Cupdo. This plasmid was digested with EcoRV to insert the marker gene *trpA* (coding for tryptophan synthase A). The tryptophan marker *trpA* was amplified using plasmid pTA132 (27) as template and oligonucleotides TRP1/TRP2, cloning of the *trpA* marker gene into the plasmid pTA131-Cupdo resulted in pTA131-CupdoTrp. Plasmids were passaged through *E. coli* GM121 to prevent methylation, and *H. volcanii* strain H119 was subsequently transformed with this construct to allow integration (pop-in) of the plasmid into the genome. The subsequent selection for loss of the *pyrE2* marker by plating on 5-fluoroorotic acid (5-FOA) revealed pop-out mutants. To confirm the removal of the gene for CRISPR locus C we performed a southern blot analysis. Chromosomal DNA was isolated from the wild type and potential locus C gene deletion mutants. Southern blot hybridisation was performed as described (27), with the following modifications: 10  $\mu$ g of SacII-digested DNA was separated on a 0.8% agarose gel and transferred to a nylon membrane (Hybond™-N, GE Healthcare). A 250 bp fragment of the downstream region of locus C was amplified using primers Cdeldoi and D0mitteC, the fragment was radioactively labelled using  $\alpha$ -<sup>32</sup>P-dCTP and random prime kit Readiprime™II (GE Healthcare) and subsequently used as a hybridisation probe (Suppl. Figure 5).

**Plasmid invader tests**- The invader plasmid construct pTA352-PAM3CSp1 (30) and pTA409-PAM3CSp1 (16) were generated based on the *Haloferax* shuttle vectors pTA352 (pHV1, *leuB*) (31) and pTA409 (pHV1, *pyrE2*) (26) including spacer 1 of the CRISPR locus C (C1) and the PAM sequence TTC (PAM3)(16,21). As a control reaction

*Haloferax* cells expressing the icrRNA (wt or mutants) were transformed with the vector without insert (pTA352 or pTA409). Plasmids were passaged through *E. coli* GM121 cells (to avoid methylation) and were then introduced into *Haloferax* cells using the PEG method (27,28). To confirm the identification of a functional invader sequence, *H. volcanii* cells were transformed at least three times with the plasmid invader construct or the control vector. For plasmid invader tests transformations with at least a 100-fold reduction in transformation rates are considered successful interference reactions (21,32). High reductions in transformation rates provide evidence for high targeting efficiency of the crRNA analysed.

**Northern blot hybridisation-** Total RNA was isolated if not stated otherwise from exponentially growing *H. volcanii* cells as described (16). After separation of 10 µg RNA (total RNA) on 8% denaturing gels, RNA molecules were transferred to nylon membranes (Hybond-N+, GE Healthcare) and incubated with oligonucleotides against the spacer 1 from locus C (primer C1). The primer was radioactively labelled at the 5' end with  $\gamma$ -<sup>32</sup>P-ATP and subsequently used for hybridisation.

**Investigation of icrRNAs-** To determine the exact length and sequence of the crRNA, RNA was isolated from wild type *Haloferax* cells (H119) and strain  $\Delta$ C x pTA232-telecRNA grown to an OD 0,74. RNA was separated on 8% PAGE and RNA ranging in size from 45-55 nucleotides (fraction 1) and from 60-75 nucleotides (fraction 2) was eluted and sent to vertis Biotechnologie AG for cDNA preparation and RNAseq analysis. The RNA samples were first treated with polynucleotide kinase (PNK) and then poly(A)-tailed using poly(A) polymerase. Afterwards, an RNA adapter was ligated to the 5'-monophosphate of the RNA. First-strand cDNA synthesis was performed using an oligo(dT)-adapter primer and the M-MLV reverse transcriptase. The resulting cDNAs were PCR-amplified to about 10-30 ng/µl using a high fidelity DNA polymerase. The cDNAs were purified using the Agencourt AMPure XP kit (Beckman Coulter Genomics) and were analysed by capillary electrophoresis. For Illumina sequencing, the cDNA samples were mixed in approximately equal amounts. An aliquot of the cDNA pool was analysed by capillary electrophoresis. The primers used for PCR amplification were designed for TruSeq

sequencing according to the instructions of Illumina.

**RNAseq mapping-** First, original reads were trimmed according to their sequencing quality using the fastq\_quality\_trimmer program from the FASTX-Toolkit version 0.0.13 with the options "-t 13 -Q 33" ([http://hannonlab.cshl.edu/fastx\\_toolkit/](http://hannonlab.cshl.edu/fastx_toolkit/)). The parameter -Q is required due to the ASCII offset of 33 used for the quality scores in the Sanger format. The estimated probability that a base call is incorrect ( $p > 0.05$ ) correspond to quality values below 13 (33). Second, trimmed reads were mapped with Segemehl (34) version 0.1.3 with the options "--polyA --prime 'AGATCGGAAGAGCGTCGTGTAGGGAAA GAGTGTAGATCTCGGTGGTCGCCGTATC ATT'".

This setting removes the poly(A) tail and the 3' Illumina sequencing adapter. The following percentages of the original reads were successfully mapped from each sample: 86 % for S1 (wild type RNA fraction of 60-75 nt length), 74 % for S2 (wild type RNA fraction of 45-55 nt length), 91 % for S3 (icrRNA fraction of 60-75 nt length), and 81 % for S4 (icrRNA fraction of 45-55 nt length). All samples had 20-40 million reads. Subsequent to mapping, alignments were filtered such that they had a maximum edit distance of 2, were located on the reverse strand (because CRISPR locus C is transcribed from the reverse strand), and matched uniquely to the genome. The filtering produced a clearer signal, but did not change original profiles. To explore and display RNAseq results, we used the Integrative Genomics Viewer (IGV) version 2.0.3 (35).

## RESULTS

To determine the essential nucleotides of the crRNA for the interference and to investigate whether the Cas6b protein is required for the interference reaction we established a Cas6b-independent crRNA generation in *H. volcanii*. Using this set up, we could study the effect of crRNA mutants on the interference reaction independently of the crRNA processing stage; thus we captured crRNA characteristics, which were specific to the interference reaction.

### **Cas protein independent generation of crRNAs**

We generated a plasmid that encodes the crRNA as well as t-elements directly up- and downstream of the crRNA (Figure 1B). The crRNA is derived from the *Haloferax* CRISPR locus C and contains spacer 1 of this locus. The

t-element is a tRNA like structure that has been previously detected directly upstream of the 5S rRNA in *H. volcanii*, it is processed by tRNase Z to generate the 5S rRNA 5' end (36,37). Generally t-elements are substrates for both tRNA processing enzymes, the 5' processing enzyme RNase P and the 3' processing enzyme tRNase Z (36,38). Processing of the t-elements up- and downstream of the crRNA should yield the mature icrRNA. We cloned the crRNA/t-element insert into the *Haloferax* vector pTA409 (26), yielding pTA409-telecRNA. A *Haloferax* strain that has the CRISPR locus C deleted (strain  $\Delta C$ ) was generated to get a strain without the endogenous spacer1 from locus C (Experimental Procedures). This strain was transformed with plasmid pTA409-telecRNA yielding  $\Delta C$  x pTA409-telecRNA. Northern blot analysis showed that an icrRNA is generated with the same size as the crRNA made in the wild type strain (that generates the crRNA from the CRISPR locus C) (Figure 1C). Thus the icrRNA is efficiently generated from the plasmid. In addition some shorter RNAs are visible, these shorter crRNAs have also been reported earlier in wild type cells (22). Since the amount of icrRNA was rather low compared to the endogenous crRNA we cloned the crRNA/t-element insert into a *Haloferax* vector with a higher copy number: pTA232 (27), yielding pTA232-telecRNA. Northern analysis showed that a *Haloferax*  $\Delta C$  strain transformed with pTA232-telecRNA generated indeed higher amounts of icrRNA (Figure 1C).

To confirm that processing of the icrRNA yielded exactly the same 5' and 3' ends as in the "natural" crRNA production we isolated the two RNA fractions that contained the long crRNA of about 65 nucleotides (RNA fraction of 60-75 nucleotides length isolated) and the shorter crRNA of about 51 nucleotides (RNA fraction of 45-55 nucleotides length isolated) from wild type *Haloferax* cells and  $\Delta C$  x pTA232-telecRNA cells and analysed them with RNAseq. The icrRNAs from the 60-75 nucleotides fraction (isolated from  $\Delta C$  x pTA232-telecRNA strain) have exactly the same 5' and 3' ends as the wild type crRNA (Figure 2A). Thus we could show that we can generate a mature icrRNA identical to the "natural" crRNA in *Haloferax* cells. In addition we could show that a slightly shorter icrRNA version with 49 nucleotides length (icrRNA<sup>49</sup>) is also present (Figure 2B). This shorter icrRNA<sup>49</sup> has the same 5' end but a 17 nucleotides shorter 3' handle than icrRNA<sup>66</sup>.

The only difference between the "natural" crRNA and the icrRNAs is the nature of the processing product end groups: the icrRNA contains a 5'-phosphate group at the crRNA 5' end and a 3' hydroxyl group at the crRNA 3' end due to processing by RNase P and tRNase Z (23,39). This is in contrast to the observed end groups generated naturally by type I Cas6 processing: a 5' hydroxyl group and 2'- 3' cyclic phosphate (I-C, I-E) (13,40,41) or a non cyclic 3' phosphate (I-F) (18). However we show here, that the nature of the end group is not important for the interference reaction (see below). Taken together we could successfully establish a Cas6b-independent crRNA maturation pathway.

#### **icrRNAs are active in interference**

To investigate whether the icrRNA is active in interference we challenged *Haloferax* strain  $\Delta C$  expressing the icrRNA (from the high copy plasmid pTA232-telecRNA) with an invader plasmid (21). The invader plasmid contains the protospacer sequence that matches spacer 1 of CRISPR locus C from *Haloferax*, thus this sequence can be detected by the icrRNA. Adjacent to the protospacer is the PAM sequence TTC that is one of the six PAMs shown to be active in *Haloferax* to trigger degradation (21). If this invader plasmid is recognised as an invader it is degraded by the defence system and cells cannot grow on selective medium. Transformation rates of strains transformed with the invader were reduced more than 100 fold compared to transformation with a control plasmid, showing that the invader plasmid is recognised and degraded (Table 2). The same experiment was subsequently carried out with the low copy icrRNA plasmid (pTA409-telecRNA). Again the transformation rates were reduced in comparison to a control plasmid, showing that the lower levels of icrRNA can also trigger the interference reaction. Taken together, the icrRNAs can trigger the interference reaction and thus are fully functional crRNAs.

#### **Cas6b is not required for interference in the presence of icrRNAs**

In the wild type situation Cas6b is required for crRNA production and it is conceivable that it could also be required for the interference reaction, since it was shown to be part of Cascade in *Haloferax* (I-B system), *E. coli* (I-E), *Pseudomonas aeruginosa* (I-F), and *Sulfolobus solfataricus* (I-A) (18,22,42-46). By the Cas6b-independent generation of icrRNAs, we separated the role of Cas6b in crRNA

processing from its function in the interference reaction. Using icrRNAs, we can now determine whether Cas6b is also important for the interference reaction. Thus we transformed a *Δcas6b* strain with pTA232-telecRNA and subsequently with the invader plasmid. The transformation rate of these cells was greatly reduced (by factor 0.0006) (Table 2), showing that the interference reaction works without Cas6b. In the *Δcas6b* strain no internal crRNAs can be generated, thus the only crRNAs present in these cells are the icrRNAs. Subsequently Cascade complexes can only be loaded with icrRNAs. This might explain the greater reduction in the transformation rate compared to  $\Delta C$ : all Cascades in *Δcas6b* contain the icrRNA directed against the invader plasmid, while in  $\Delta C$  only a percentage of the Cascade complexes are loaded with an icrRNA, since the crRNAs from CRISPR locus P1 and P2 are also present.

Taken together the Cas6b protein is not required for the interference reaction when the icrRNA is present.

#### **Essential features of the crRNA 5' handle**

Since the icrRNA was proven to be identical to the "naturally" expressed crRNA and to be fully active in interference, we generated different versions of the icrRNA to analyse the essential features of a crRNA for the interference reaction. To identify the important nucleotides of the 5' handle we generated ten different variants and analysed them for activity in the interference reaction (Table 3). All variants were transformed into strain *Δcas6b* that was subsequently challenged with the invader plasmid. First we mutated the first nucleotide of the crRNA (which is a G) to a A, U or C (variants 4-6). Mutation of the first nucleotide (position -8) results in icrRNAs that are as effective in interference as the wild type icrRNA (Table 3). This is in agreement with the *in vivo* situation in *Haloferax*, where the crRNAs are generated from three different CRISPR loci, that each have a different nucleotide at position -8 of the 5' handle (Figure 1A). Second, the -1 nucleotide was mutated from C to U, G and A (variants 8-10). This nucleotide has been shown in *E. coli* (type I-E) to be derived from the invader (47-49). In *Haloferax* the nucleotide -1 is a C and thus also identical to the last nucleotide of the PAM used in this study (TTC). It has therefore the potential to base pair with the invader (Figure 3A). Mutation of this nucleotide to a U does not interfere with the defence activity. The U at this

position could still base pair with the complementary PAM sequence in the invader (U-G base pair) (Figure 3B). Mutation of the -1 nucleotide to a G however abolishes the defence activity, this nucleotide could not base pair anymore with the complementary PAM sequence (GxG) (Figure 3C). Surprisingly, mutation of this nucleotide from C to an A does not interfere with the defence activity, although an A at this position is not able to base pair with the complementary PAM sequence in the invader (GxA) (Figure 3D).

Since the nature of the first crRNA nucleotide is not important, we next deleted this nucleotide, generating an icrRNA that is still active in interference. Deletion of the first two nucleotides results however in an icrRNA inactive in interference. A deletion of three nucleotides in the 5' handle (positions -6 to -4) (variant 7) is not tolerated. The complete removal of the 5' handle (variant 3) results in a crRNA that cannot trigger the interference reaction anymore.

Taken together mutations in the 5' handle are tolerated at the first nucleotide (position -8) and to some extent at position -1. Only the deletion of the first nucleotide of the 5' handle is tolerated, all other deletions result in inactive icrRNAs.

#### **Essential features of the crRNA 3' handle**

The crRNA 3' handle in *Haloferax* has the potential to form a short stem loop structure at the very 3' end (Figure 1A). To determine whether parts of this stem loop are required and to define the essential features of the 3' handle we constructed thirteen icrRNA variants with mutations in the 3' handle and analysed their activity in interference (Table 4). We mutated a nucleotide in the loop of the potential stem loop structure (G to C or U)(variants 11-12). These variants were both still active in triggering the interference reaction. The removal of four nucleotides of the 3' handle in variant 1 (positions 8-11 in the 3' handle) also did not interfere with the interference reaction. Likewise did the removal of eleven nucleotides in variant 2 (positions 1-11) not reduce the interference. The nature of the 3' handle differs from CRISPR system to CRISPR system. In *Haloferax* wild type cells two types of crRNAs are observed having a 3' handle of approx. 22 nucleotides and of approx. 5 nucleotides (22). A similar observation was made with the icrRNA, since a long and a short icrRNA can be detected (Figure 1C and Figure 2B), that contain a 22 nucleotide and a five nucleotide 3' handle

(Figure 2B). To investigate how many nucleotides can be removed from the 3' handle we designed several 3' handle deletion variants. The five terminal nucleotides were deleted in variant 13, ten terminal nucleotides were removed in variant 14, the last 15 and 20 nucleotides were deleted in variant 15 and 16, respectively. The interference tests clearly show that all four deletions in the 3' handle had no effect on the interference activity (Table 4). In variant 20 only one nucleotide of the 3' handle remained, but still this crRNA was effective in triggering the interference reaction. This last nucleotide was mutated in variants 21-23 from a G to a C, A or U. Again all variants were still active. Even a complete removal of all 22 nucleotides (variant 19) did not interfere with the interference reaction. These results also suggest that the exact length of the complete crRNA is not important, since different lengths at the 3' handle are tolerated.

## DISCUSSION

We could successfully establish a Cas6b-independent crRNA maturation pathway in *Haloferax* cells. In this pathway icrRNAs are excised from a precursor with the help of tRNA processing enzymes, resulting in small RNAs active in the interference reaction. The icrRNAs are identical to the "natural" crRNAs except for the nature of the end groups.

### **Cas6b is only required for crRNA maturation in type I-B**

Using the independently generated crRNA we could show that Cas6b is not required for any other reactions besides crRNA processing in the prokaryotic immune system I-B. As soon as the crRNA is generated without Cas6b this protein is dispensable, since it is not required for the interference reaction. We previously showed that Cas6b copurifies with Cascade in *Haloferax* (22), this observation might be due to the fact, that the crRNA is incorporated into Cascade and that Cas6b is still bound to the crRNA thereby co-purifying with the FLAG tagged Cas7. But although it copurifies with Cas5 and Cas7 it is not required to be part of the I-B Cascade for activity. Thus the core part of the I-B Cascade seems to consist of Cas5, Cas7 and the crRNA. These results are confirmed by the observation that the 3' handle can be completely removed. Thus if the Cas6b protein is attached to Cascade via binding to the crRNA 3' handle, this interaction is not essential.

### **Essential parts of the 5' handle**

Recent reports on the structure of the *E. coli* Cascade complex revealed, that the first seven nucleotides of the crRNA 5' handle form a hook that interacts with the Cas5, Cas7 and Cse1 proteins (the homologous protein in *Haloferax* would be the Cas8b protein) (42-44). Our data clearly show that in the *Haloferax* I-B system the 5' handle is also an important part of the crRNA. Only the first nucleotide of the 5' handle can be mutated and deleted without loss of activity. This is in agreement with the *in vivo* situation where 3 different 5' handles are generated (Figure 1A.). In the structural analyses reported for the I-E Cascade complex, the first nucleotide of the 5' handle interacts with Cas5 and Cas7 (42-44). In the *Haloferax* system this interaction does not seem to be crucial for the activity. However, all other deletions in the 5' handle abolished interference activity: deletions of the first two nucleotides, of three internal nucleotides and of all 5' handle nucleotides yield a non functional crRNA, confirming the importance of the 5' handle.

### **Interaction of the crRNA 5' handle with the protospacer adjacent motif**

The nature of the last nucleotide of the 5' handle (position -1) seems to be important: mutation of this nucleotide from C to G results in loss of activity, only nucleotides C, A and U are tolerated at this position. In *E. coli* it has been shown that the -1 crRNA nucleotide is identical to the last PAM nucleotide and is derived from the invader (47-51), thus the crRNA could base pair with the invader at this position (Figure 3). It is not known whether the crRNA 5' handle nucleotide (position -1) stems from the invader in the *Haloferax* I-B system. But the -1 crRNA nucleotide and invader complementary PAM nucleotide (in PAMs TTC and CAC, two of the six PAMs recognised by *Haloferax*) have also the potential to base pair. This base pair might be important for recognising the correct target DNA sequence. The observation that the -1 nucleotide mutant C to U works but C to G does not work would confirm this hypothesis. However, the result that the C to A mutation is still active in interference does not fit. In addition, the complementary nucleotide of the other four PAMs recognised in the *Haloferax* system (TAT, TAA, TAG, ACT) cannot base pair with the crRNA. In the I-E and I-F *E. coli* system it has been shown that the interaction between the -1 crRNA nucleotide and the last complementary PAM nucleotide is not essential



for invader recognition (52,53). The recent structural data for the I-E Cascade complex confirm this earlier observation showing that in this system the -1 nucleotide of the crRNA is displaced by the Cas5 protein preventing interaction with the invader PAM sequence. The same displacement of the -1 nucleotide might happen in the *Haloferax* I-B Cascade. And the loss of activity of the C → G mutant could be explained by failure of the G to interact properly with the Cas5 protein.

In the I-E system Cse1 (the homologous protein in *Haloferax* is Cas8b) interacts with the PAM sequence and target recognition occurs via identification of the PAM sequence by the Cse1 protein (18,53-55). The same might be true for the *Haloferax* I-B system but the Cas8b protein should be able to identify six different PAMs: TTC, CAC, TAT, TAA, TAG and ACT.

Taken together our results suggest that a G at position -1 cannot interact properly with the Cas5 protein and that the *Haloferax* Cas8b would have to recognise all six different PAMs.

#### **Essential parts of the 3' handle**

Mutational analysis of the icrRNA showed that the 3' handle of the crRNA is completely dispensable. The shortest icrRNA found *in vivo* by RNAseq contained a five nucleotide long 3' handle. According to the data reported here, this shorter crRNA version with only 49 nucleotides should also be active, since even an icrRNA with no 3' handle is still active. Previous isolation of crRNAs from the *Haloferax* Cascade like complex showed that the long and the short crRNA versions co-purify (22). It would be interesting to analyse whether only the short form is the active form and whether the long form has to be activated by 3' processing to yield the short functional form. Currently it is not known which enzyme(s) are catalysing this further trimming of the crRNA 3' end. As soon as this enzyme is identified we could generate a strain that has the gene for this enzyme deleted and analyse whether the icrRNA with a long unprocessed 3' handle is active.

A shortening of the crRNA 3' handle has also been reported for the type I-B system of *Methanococcus maripaludis* and *Clostridium thermocellum* (56). Thus it seems that in contrast to the I-A, I-E and I-F systems crRNAs of the I-B system are subjected to an additional 3' trimming, as reported for the crRNAs in type III systems (14,15).

#### **The nature of the crRNA end group is not important**

The pre-icrRNA is generated by the tRNA processing enzymes to exactly the same product as the pre-crRNA generation by Cas6b. The only difference between the natural crRNA and the icrRNA is the nature of the 5' and 3' end groups. However in the experiments reported here, the nature of the end groups did not have any effect: neither on the shortening of the icrRNA<sup>66</sup> to icrRNA<sup>49</sup> nor on the interference reaction. Taken together the nature of the end groups seems not important for the interference reaction.

#### **The minimal type I-B crRNA**

Previously published data concerning the requirements for the spacer-protospacer interactions in the *Haloferax* I-B system showed that a 34 nucleotide long spacer-protospacer interaction between crRNA and invader was sufficient (16). According to these published data and the results reported here the minimal crRNA for the *Haloferax* type I-B system contains a seven nucleotide long 5' handle, a 34 nucleotide long spacer and no 3' handle (Figure 4). Altogether this crRNA would be 41 nucleotides long.

#### **Acknowledgments**

We are grateful to Charles J. Daniels for providing us with the synthetic promoter and terminator sequences for *Haloferax* ahead of publication. We thank Elli Bruckbauer for her expert technical assistance and Jutta Brendel for her kind help. We are grateful to all members of the FOR Unit 1680 for helpful discussions.



## REFERENCES

1. Marchfelder, A., Fischer, S., Brendel, J., Stoll, B., Maier, L. K., Jager, D., Prasse, D., Plagens, A., Schmitz, R. A., and Randau, L. (2012) Small RNAs for defence and regulation in archaea *Extremophiles* **16**, 685-696
2. Westra, E. R., Swarts, D. C., Staals, R. H., Jore, M. M., Brouns, S. J., and van der Oost, J. (2012) The CRISPRs, They Are A-Changin': How Prokaryotes Generate Adaptive Immunity *Annu Rev Genet.* **46**:311-39., 10.1146/annurev-genet-110711-155447.
3. Barrangou, R., and Marraffini, L. A. (2014) CRISPR-Cas systems: Prokaryotes upgrade to adaptive immunity *Mol Cell.* **54**, 234-244. doi: 210.1016/j.molcel.2014.1003.1011.
4. Terns, M. P., and Terns, R. M. (2011) CRISPR-based adaptive immune systems *Curr Opin Microbiol* **14**, 321-327. Epub 2011 Apr 2029.
5. Bhaya, D., Davison, M., and Barrangou, R. (2011) CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation *Annu Rev Genet* **45**, 273-297.
6. Bikard, D., and Marraffini, L. A. (2013) Control of gene expression by CRISPR-Cas systems *1000Prime* **5**, 47
7. Makarova, K. S., Haft, D. H., Barrangou, R., Brouns, S. J., Charpentier, E., Horvath, P., Moineau, S., Mojica, F. J., Wolf, Y. I., Yakunin, A. F., van der Oost, J., and Koonin, E. V. (2011) Evolution and classification of the CRISPR-Cas systems *Nature Reviews Microbiology* **9**, 467-477. Epub 2011 May 2019.
8. Mojica, F. J., Diez-Villasenor, C., Garcia-Martinez, J., and Almendros, C. (2009) Short motif sequences determine the targets of the prokaryotic CRISPR defence system *Microbiology.* **155**, 733-740.
9. Charpentier, E., van der Oost, J., and White, M. F. (2013) crRNA biogenesis. in *CRISPR-Cas systems* (Barrangou, R., and van der Oost, J. eds.), Springer - Verlag, Berlin - Heidelberg. pp 115-144
10. Chylinski, K., Le Rhun, A., and Charpentier, E. (2013) The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems *RNA Biol.* **10**, 726-737. doi: 710.4161/rna.24321. Epub 22013 Apr 24325.
11. Vestergaard, G., Garrett, R. A., and Shah, S. A. (2014) CRISPR adaptive immune systems of Archaea *RNA Biol.* **11**, 156-167. doi: 110.4161/rna.27990. Epub 22014 Feb 27997.
12. Reeks, J., Naismith, J. H., and White, M. F. (2013) CRISPR interference: a structural perspective *Biochem J.* **453**, 155-166. doi: 110.1042/BJ20130316.
13. Carte, J., Wang, R., Li, H., Terns, R. M., and Terns, M. P. (2008) Cas6 is an endoribonuclease that generates guide RNAs for invader defense in prokaryotes *Genes Dev.* **22**, 3489-3496.
14. Hatoum-Aslan, A., Maniv, I., and Marraffini, L. A. (2011) Mature clustered, regularly interspaced, short palindromic repeats RNA (crRNA) length is measured by a ruler mechanism anchored at the precursor processing site *Proc Natl Acad Sci U S A.* **108**, 21218-21222. Epub 22011 Dec 21212.
15. Hale, C. R., Zhao, P., Olson, S., Duff, M. O., Graveley, B. R., Wells, L., Terns, R. M., and Terns, M. P. (2009) RNA-guided RNA cleavage by a CRISPR RNA-Cas protein complex *Cell.* **139**, 945-956. doi: 910.1016/j.cell.2009.1007.1040.
16. Maier, L. K., Lange, S. J., Stoll, B., Haas, K. A., Fischer, S., Fischer, E., Duchardt-Ferner, E., Wohnert, J., Backofen, R., and Marchfelder, A. (2013) Essential requirements for the detection and degradation of invaders by the *Haloferax volcanii* CRISPR/Cas system I-B *RNA Biol* **10**, 865-874
17. Semenova, E., Jore, M. M., Datsenko, K. A., Semenova, A., Westra, E. R., Wanner, B., van der Oost, J., Brouns, S. J., and Severinov, K. (2011) Interference by clustered regularly interspaced short palindromic repeat (CRISPR) RNA is governed by a seed sequence *Proc Natl Acad Sci USA* **108**, 10098-10103. Epub 12011 Jun 10096.
18. Wiedenheft, B., van Duijn, E., Bultema, J. B., Waghmare, S. P., Zhou, K., Barendregt, A., Westphal, W., Heck, A. J., Boekema, E. J., Dickman, M. J., and Doudna, J. A. (2011) RNA-guided complex from a bacterial immune system enhances target recognition through seed sequence interactions *Proc Natl Acad Sci U S A.* **108**, 10092-10097. Epub 12011 May 10092.

19. Künne, T., Swarts, D. C., and Brouns, S. J. (2014) Planting the seed: target recognition of short guide RNAs *Trends Microbiol.* **22**, 74-83. doi: 10.1016/j.tim.2013.1012.1003. Epub 2014 Jan 1014.
20. Maier, L. K., Stoll, B., Brendel, J., Fischer, S., Pfeiffer, F., Dyall-Smith, M., and Marchfelder, A. (2013) The ring of confidence: a haloarchaeal CRISPR/Cas system *Biochem Soc Trans.* **41**, 374-378. doi: 310.1042/BST20120263.
21. Fischer, S., Maier, L. K., Stoll, B., Brendel, J., Fischer, E., Pfeiffer, F., Dyall-Smith, M., and Marchfelder, A. (2012) An archaeal immune system can detect multiple protospacer adjacent motifs (PAMs) to target invader DNA *J Biol Chem* **287**, 33351-33365
22. Brendel, J., Stoll, B., Lange, S. J., Sharma, K., Lenz, C., Stachler, A. E., Maier, L. K., Richter, H., Nickel, L., Schmitz, R. A., Randau, L., Allers, T., Urlaub, H., Backofen, R., and Marchfelder, A. (2014) A complex of Cas proteins 5, 6, and 7 is required for the biogenesis and stability of crRNAs in *Haloferax volcanii* *J Biol Chem* **289**, 7164-7177
23. Hartmann, R. K., Gössringer, M., Späth, B., Fischer, S., and Marchfelder, A. (2009) The making of tRNAs and more - RNase P and tRNase Z *Prog Mol Biol Transl Sci.* **85**, 319-368.
24. Allers, T., Barak, S., Liddell, S., Wardell, K., and Mevarech, M. (2010) Improved strains and plasmid vectors for conditional overexpression of His-tagged proteins in *Haloferax volcanii* *Appl Environ Microbiol* **76**, 1759-1769
25. Miller, J. H. (1972) *Experiments in Molecular Genetics*, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, N. Y.
26. Delmas, S., Shunburne, L., Ngo, H. P., and Allers, T. (2009) Mre11-Rad50 promotes rapid repair of DNA damage in the polyploid archaeon *Haloferax volcanii* by restraining homologous recombination *PLoS Genet.* **5**, e1000552. Epub 1002009 Jul 1000510.
27. Allers, T., Ngo, H. P., Mevarech, M., and Lloyd, R. G. (2004) Development of additional selectable markers for the halophilic archaeon *Haloferax volcanii* based on the *leuB* and *trpA* genes *Appl Environ Microbiol* **70**, 943-953
28. Cline, S. W., Schalkwyk, L. C., and Doolittle, W. F. (1989) Transformation of the archaeobacterium *Halobacterium volcanii* with genomic DNA *J Bacteriol.* **171**, 4987-4991.
29. Fischer, S., Benz, J., Späth, B., Maier, L.-K., Straub, J., Granzow, M., Raabe, M., Urlaub, H., Hoffmann, J., Brutschy, B., Allers, T., Soppa, J., and Marchfelder, A. (2010) The archaeal Lsm protein binds to small RNAs *J Biol Chem* **285**, 34429-34438
30. Stoll, B. (2013) Analyse des prokaryotischen Immunsystems CRISPR/Cas Typ I-B im archaealen Modellorganismus *Haloferax volcanii*. in *Biology II*, Ulm University, Ulm
31. Norais, C., Hawkins, M., Hartman, A. L., Eisen, J. A., Myllykallio, H., and Allers, T. (2007) Genetic and physical mapping of DNA replication origins in *Haloferax volcanii* *PLoS Genet.* **3**, e77. Epub 2007 Apr 2005.
32. Gudbergsdottir, S., Deng, L., Chen, Z., Jensen, J. V., Jensen, L. R., She, Q., and Garrett, R. A. (2011) Dynamic properties of the *Sulfolobus* CRISPR/Cas and CRISPR/Cmr systems when challenged with vector-borne viral and plasmid genes and protospacers *Mol Microbiol* **79**, 35-49
33. Cock, P. J., Fields, C. J., Goto, N., Heuer, M. L., and Rice, P. M. (2010) The Sanger FASTQ file format for sequences with quality scores, and the Solexa/Illumina FASTQ variants *Nucleic Acids Res.* **38**, 1767-1771. doi: 1710.1093/nar/gkp1137. Epub 2009 Dec 1716.
34. Hoffmann, S., Otto, C., Kurtz, S., Sharma, C. M., Khaitovich, P., Vogel, J., Stadler, P. F., and Hackermüller, J. (2009) Fast mapping of short sequences with mismatches, insertions and deletions using index structures *PLoS Comput Biol.* **5**, e1000502. Epub 1002009 Sep 1000511.
35. Robinson, J. T., Thorvaldsdottir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., and Mesirov, J. P. (2011) Integrative genomics viewer *Nat Biotechnol.* **29**, 24-26.
36. Hölzle, A., Fischer, S., Heyer, R., Schütz, S., Zacharias, M., Walther, P., Allers, T., and Marchfelder, A. (2008) Maturation of the 5S rRNA 5' end is catalyzed in vitro by the endonuclease tRNase Z in the archaeon *H. volcanii* *RNA* **14**, 928-937.
37. Hölzle, A., Stoll, B., Schnattinger, T., Schöning, U., Tjaden, B., and Marchfelder, A. (2012) tRNA-like elements in *Haloferax volcanii* *Biochimie.* **94**, 940-946. Epub 2011 Dec 2018.
38. Gopalan, V., Vioque, A., and Altman, S. (2002) RNase P: variations and uses *J Biol Chem.* **277**, 6759-6762. Epub 2001 Dec 6710.

39. Schierling, K., Rösch, S., Rupprecht, R., Schiffer, S., and Marchfelder, A. (2002) tRNA 3' end maturation in archaea has eukaryotic features: the RNase Z from *Haloferax volcanii* *J Mol Biol* **316**, 895-902
40. Garside, E. L., Schellenberg, M. J., Gesner, E. M., Bonanno, J. B., Sauder, J. M., Burley, S. K., Almo, S. C., Mehta, G., and MacMillan, A. M. (2012) Cas5d processes pre-crRNA and is a member of a larger family of CRISPR RNA endonucleases *RNA*. **18**, 2020-2028. doi: 10.1261/rna.033100.033112. Epub 032012 Sep 033124.
41. Jore, M. M., Lundgren, M., van Duijn, E., Bultema, J. B., Westra, E. R., Waghmare, S. P., Wiedenheft, B., Pul, Ü., Wurm, R., Wagner, R., Beijer, M. R., Barendregt, A., Zhou, K., Snijders, A. P., Dickman, M. J., Doudna, J. A., Boekema, E. J., Heck, A. J., van der Oost, J., and Brouns, S. J. (2011) Structural basis for CRISPR RNA-guided DNA recognition by Cascade *Nat Struct Mol Biol* **18**, 529-536
42. Jackson, R. N., Golden, S. M., van Erp, P. B., Carter, J., Westra, E. R., Brouns, S. J., van der Oost, J., Terwilliger, T. C., Read, R. J., and Wiedenheft, B. (2014) Crystal structure of the CRISPR RNA-guided surveillance complex from *Escherichia coli* *Science* **345**, 1473-1479
43. Mulepati, S., Heroux, A., and Bailey, S. (2014) Crystal structure of a CRISPR RNA-guided surveillance complex bound to a ssDNA target *Science* **345**, 1479-1484
44. Zhao, H., Sheng, G., Wang, J., Wang, M., Bunkoczi, G., Gong, W., Wei, Z., and Wang, Y. (2014) Crystal structure of the RNA-guided immune surveillance Cascade complex in *Escherichia coli* *Nature* **12**
45. Lintner, N. G., Kerou, M., Brumfield, S. K., Graham, S., Liu, H., Naismith, J. H., Sdano, M., Peng, N., She, Q., Copié, V., Young, M. J., White, M. F., and Lawrence, C. M. (2011) Structural and Functional Characterization of an Archaeal Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated Complex for Antiviral Defense (CASCADE) *J Biol Chem* **286**, 21643-21656
46. Brouns, S. J., Jore, M. M., Lundgren, M., Westra, E. R., Slikhuis, R. J., Snijders, A. P., Dickman, M. J., Makarova, K. S., Koonin, E. V., and van der Oost, J. (2008) Small CRISPR RNAs guide antiviral defense in prokaryotes *Science*. **321**, 960-964.
47. Datsenko, K. A., Pougach, K., Tikhonov, A., Wanner, B. L., Severinov, K., and Semenova, E. (2012) Molecular memory of prior infections activates the CRISPR/Cas adaptive bacterial immunity system *Nat Commun.* **3:945**, 10.1038/ncomms1937.
48. Goren, M. G., Yosef, I., Auster, O., and Qimron, U. (2012) Experimental definition of a clustered regularly interspaced short palindromic duplicon in *Escherichia coli* *J Mol Biol.* **423**, 14-16. doi: 10.1016/j.jmb.2012.1006.1037. Epub 2012 Jul 1013.
49. Swarts, D. C., Mosterd, C., van Passel, M. W., and Brouns, S. J. (2012) CRISPR interference directs strand specific spacer acquisition *PLoS One.* **7**, e35888. doi: 10.1371/journal.pone.0035888. Epub 032012 Apr 0035827.
50. Sinkunas, T., Gasiunas, G., Waghmare, S. P., Dickman, M. J., Barrangou, R., Horvath, P., and Siksnys, V. (2013) In vitro reconstitution of Cascade-mediated CRISPR immunity in *Streptococcus thermophilus* *EMBO J.* **32**, 385-394. doi: 10.1038/emboj.2012.1352. Epub 2013 Jan 1018.
51. Dupuis, M. E., and Moineau, S. (2013) Type II: *Streptococcus thermophilus*. in *CRISPR-Cas systems* (Barrangou, R., and van der Oost, J. eds.), Springer - Verlag, Berlin - Heidelberg. pp 171-200
52. Almendros, C., Guzman, N. M., Diez-Villasenor, C., Garcia-Martinez, J., and Mojica, F. J. (2012) Target motifs affecting natural immunity by a constitutive CRISPR-Cas system in *Escherichia coli* *PLoS One.* **7**, e50797. doi: 10.1371/journal.pone.0050797. Epub 052012 Nov 0050726.
53. Westra, E. R., Semenova, E., Datsenko, K. A., Jackson, R. N., Wiedenheft, B., Severinov, K., and Brouns, S. J. (2013) Type I-E CRISPR-cas systems discriminate target from non-target DNA through base pairing-independent PAM recognition *PLoS Genet.* **9**, e1003742. doi: 10.1371/journal.pgen.1003742. Epub 1002013 Sep 1003745.
54. Sashital, D. G., Wiedenheft, B., and Doudna, J. A. (2012) Mechanism of foreign DNA selection in a bacterial adaptive immune system *Mol Cell.* **46**, 606-615. doi: 10.1016/j.molcel.2012.1003.1020. Epub 2012 Apr 1019.

55. Sternberg, S. H., Haurwitz, R. E., and Doudna, J. A. (2012) Mechanism of substrate selection by a highly specific CRISPR endoribonuclease *RNA*. **18**, 661-672. doi: 610.1261/rna.030882.030111. Epub 032012 Feb 030816.
56. Richter, H., Zoepfel, J., Schermuly, J., Maticzka, D., Backofen, R., and Randau, L. (2012) Characterization of CRISPR RNA processing in *Clostridium thermocellum* and *Methanococcus maripaludis* *Nucleic Acids Res.* **40**, 9887-9896. doi: 9810.1093/nar/gks9737. Epub 2012 Aug 9888.

## FOOTNOTES

1 Abbreviations: CRISPR: clustered regularly interspaced short palindromic repeats-CRISPR associated, Cas: CRISPR associated, crRNA: CRISPR RNA, icrRNA: independently generated crRNA

2 The Cas proteins Cas6 and Cas8 are termed Cas6b and Cas8b in CRISPR-Cas type I-B.

## TABLE AND FIGURE LEGENDS

**Table 1. Strains, plasmids and primers used in this study.**

**Table 2. Interference test with the icrRNA.** Targeting efficiencies of the icrRNAs expressed from the high copy and low copy icrRNA plasmids were analysed. The targeting efficiency of the icrRNAs expressed from the high copy icrRNA plasmid were investigated in strain  $\Delta C$  and  $\Delta cas6b$ . A successful interference reaction reduces the transformation rate by at least factor 0.01, demonstrating a high targeting efficiency of the icrRNA (21). If the plasmid is not recognised as an invader and not destroyed, the transformation rate is the same as with a "normal" plasmid, there is no reduction of transformation rate. If the plasmid is recognised as an invader and degraded, cells cannot survive on  $ura^-$  medium. However, some cells can inactivate the CRISPR-Cas system (by deleting or mutating the *cas* genes or the genes for the CRISPR RNAs) and can grow on the selective medium (21). As a result the plates are not completely empty since the mutated *Haloferax* cells can grow. Therefore a high targeting efficiency is defined by a reduction in transformation rate by at least 0.01 (21).

**Table 3. The crRNA 5' handle is essential.** Ten different variants of the icrRNA with different mutations in the 5' handle were generated. The reduction of transformation rates upon transformation of  $\Delta C$  x pTA232-telecRNA with invader plasmid is shown (column "reduction of transformation rate by factor"), demonstrating the targeting efficiency of the icrRNA variants. A successful interference reaction reduces the transformation rate by at least factor 0.01 (21). If the plasmid is not recognised as an invader and not destroyed the transformation rate is the same as with a "normal" plasmid, there is no reduction of transformation rate.

**Table 4. The crRNA 3' handle can be omitted.** Thirteen different variants of the icrRNA with different mutations in the 3' handle were generated. The reduction of transformation rates upon transformation with invader plasmids is shown (column "reduction of transformation rate by factor"), demonstrating the targeting efficiency of the icrRNA variants. A successful interference reaction reduces the transformation rate by at least factor 0.01 (21). If the plasmid is not recognised as an invader and not destroyed the transformation rate is the same as with a "normal" plasmid, there is no reduction of transformation rate.

**Figure 1. The natural crRNA of *Haloferax* and the icrRNA. A. The crRNAs of *Haloferax*.** *Haloferax* encodes three different CRISPR loci, P1, P2 and C, that have the same 30 nucleotide long repeat sequences except for the first nucleotide of the 5' handle (position -8 according to the nomenclature (42-44)), that is an A in P1, a U in P2 and a G in C. Thus there are three types of crRNAs in *Haloferax* beginning with three different nucleotides. The mature crRNA contains an 8 nucleotide 5' handle and a 22 nucleotide 3' handle. Spacers are between 34 and 39 nucleotides long. Nucleotides in the 5' handle are termed -8 to -1 (from the 5' end of the 5' handle), nucleotides from the 3' handle are termed +1 to +22 (42-44). **B. Maturation of the icrRNA.** The pre-icrRNA contains the crRNA flanked by two t-elements. The crRNA is derived from CRISPR locus C containing spacer 1 from this locus. The t-elements are recognised and processed by RNase P and tRNase Z, generating the mature icrRNA of 66 nucleotides (icrRNA<sup>66</sup>). This icrRNA can be processed further to a 49 nucleotides long icrRNA<sup>49</sup> by as yet unknown RNases. **C. Maturation of the icrRNA in *Haloferax* cells.** RNA was isolated from wild type cells (lane wt), *Haloferax* cells without the CRISPR locus C (lane  $\Delta C$ ) and  $\Delta C$  cells with pTA409-telecRNA (lane  $\Delta C$  + in the left panel) and from  $\Delta C$  cells with the high copy plasmid pTA232-telecRNA (lane  $\Delta C$  + in the right panel), respectively. After separation on 8% PAGE the RNA was transferred to a membrane which was subsequently hybridised with a probe against the crRNA. The mature crRNA can be detected in wild type *Haloferax* cells but not in  $\Delta C$ . **Left panel "low copy": Generation of icrRNAs from low copy plasmids.** The mature icrRNA can be detected in  $\Delta C$  transformed with the low copy plasmid pTA409-telecRNA. Lane m: DNA size marker, sizes are given at the left in nucleotides. The icrRNAs are shown schematically at the right. **Right panel: "high copy": Generation of icrRNAs from high copy plasmids.** In lane  $\Delta C$  + the precursor of the icrRNA as well as the processing intermediates are visible. The long exposure (bottom right "long") shows that the shorter icrRNA of about 49 nucleotides is also present.

Sizes of a DNA marker are given at the left in nucleotides. The precursor of the icrRNA, the intermediates and the mature icrRNA are shown schematically at the right.

**Figure 2. Determination of crRNA and icrRNA sequences with RNAseq. A. Comparison of Cas6b catalysed crRNA generation (wt) and Cas6b independent crRNA production (icrRNA).** RNAseq data from RNA fractions (sizes 60-75 nucleotides) isolated from wild type *Haloferax* cells (upper row "wt") and  $\Delta C$  x pTA232-telecRNA (lower row "icrRNA") were mapped to the CRISPR C locus. The icrRNA only comprises of spacer 1, between the repeats 1 and 2. The numbers to the right of each row reflect the number of reads mapping to this region. The dominant crRNA length is 66 nt, each mature crRNA begins with the characteristic eight nucleotide handle at its 5' end and ends with the remaining 22 nucleotides of the repeat. Both pathways produce the same mature crRNA. **B. Two types of icrRNA are generated.** In  $\Delta C$  x pTA232-telecRNA, in addition to the 66 nucleotides long icrRNA, a shorter icrRNA of 49 nt is also evident (Figure 1C). RNAseq data from the longer icrRNA fraction (sizes 60-75 nucleotides) isolated from  $\Delta C$  x pTA232-telecRNA *Haloferax* cells (upper row "long icrRNA") and from the shorter icrRNA fraction (sizes 45-55 nucleotides)(lower row "short icrRNA") were mapped to the CRISPR C locus. Each icrRNA begins with the characteristic eight nucleotide 5' handle, followed by the spacer sequence. In contrast to the long crRNAs, the shorter crRNAs contain only a five nucleotide long 3' handle.

**Figure 3. Interaction of the crRNA with the complementary PAM sequence.** Details of the interaction between crRNA and invader plasmid DNA are shown. The spacer sequence of the crRNA base pairs with the protospacer sequence (except for every sixth nucleotide.) The PAM sequence and its complementary sequence are shown in green. The protospacer sequence is shown in yellow. The last three nucleotides (-3 to -1) of the crRNA are shown. The -1 crRNA nucleotide is located directly opposite of the third complementary PAM nucleotide. **A.** In the wild type crRNA the -1 nucleotide is a C that can base pair with the third complementary PAM nucleotide G. **B.** In crRNA variant 8 the -1 nucleotide is a U that can base pair with the complementary PAM nucleotide G. **C.** In variant 9 the -1 nucleotide is a G that cannot base pair with G. **D.** In variant 10 the -1 nucleotide is an A that cannot base pair with the third complementary PAM nucleotide G. The functionality of each crRNA is indicated with "active" or "not active".

**Figure 4. The minimal crRNA.** The minimal crRNA for the defence reaction in *Haloferax* consists of a 7 nucleotide 5' handle and a 34 nucleotide long spacer.

**Table 1.**












<b>Strains</b>	<b>Genotype</b>	<b>Reference</b>
DH5 $\alpha$	F- $\phi$ 80/ <i>lacZ</i> $\Delta$ M15 $\Delta$ ( <i>lacZYA-argF</i> ) U169 <i>recA1 endA1 hsdR17</i> (rk-, mk+) <i>gal- phoA supE44 <math>\lambda</math>- thi-1 gyrA96 relA1</i>	Invitrogen
GM121	F- <i>dam-3 dcm-6 ara-14 fhuA31 galK2 galT22 hdsR3 lacY1 leu-6 thi-1 thr-1 tsx-78</i>	(24)
H119	$\Delta$ <i>pyrE2</i> $\Delta$ <i>trpA</i> $\Delta$ <i>leuB</i>	(27)
$\Delta$ <i>cas6</i>	$\Delta$ <i>pyrE2</i> , $\Delta$ <i>leuB</i> , $\Delta$ <i>trpA</i> , $\Delta$ <i>cas6</i>	(22)
$\Delta$ C	$\Delta$ <i>pyrE2</i> , $\Delta$ <i>leuB</i> , $\Delta$ <i>trpA</i> , $\Delta$ HVO_2,385,045-2,386,660:: <i>trpA</i>	This study
<b>Plasmids</b>	<b>Relevant properties</b>	<b>Reference</b>
pTA409	shuttle vector with <i>pyrE2</i> marker and pHV1 replication origin	(26)
pTA352	shuttle vector with <i>leuB</i> marker and pHV1 replication origin	(31)
pTA409-PAM3CSp1	spacer C1 downstream of PAM3 (TTC)	(16)
pTA352-PAM3CSp1	spacer C1 downstream of PAM3 (TTC)	(30)
pMA-RQ-telecRNA	<i>E. coli</i> plasmid containing the promoter, crRNA flanked by t-elements and terminator, expressing the icrRNA	This study
pMA-telecRNA	<i>E. coli</i> plasmid containing the promoter, crRNA flanked by t-elements and terminator, expressing the icrRNA	This study
pTA409-telecRNA	plasmid containing the promoter, crRNA flanked by t-elements and terminator, expressing the icrRNA	This study
pTA232-telecRNA	plasmid containing the promoter, crRNA flanked by t-elements and terminator, expressing the icrRNA	This study
pTA232-telecRNAX	like pTA232-telecRNA but containing telecrRNA mutants (X=1-23)	This study
pTA131Cup	upstream region of CRISPR RNA gene locus C	This study
pTA131-Cupdo	up and downstream regions of CRISPR RNA gene locus C	This study
pTA131-CupdoTrp	up and downstream regions of CRISPR RNA gene locus C flanking the <i>trpA</i> marker gene	This study
<b>Primers</b>	<b>Sequence</b>	<b>Reference</b>
itele1	ACCGATATTGGTATGGCAACC	This study
del1	AAGGGTTCGTCTGAACTTTCTG	This study
del2	TTCGTCTGAACTTTCTGAGATTC	This study
del3	CTGAACTTTCTGAGATTCGAGG	This study
del4	ACTTTCTGAGATTCGAGGGCATC	This study
C-SP1	CTGAGATTCGAGGGCATCTTCGGACCTTTCC	This study
DOmitteC	GAGAAGCTTAAATACAACCA	This study
Cdelup	TATAGGTACCCGCTCGTCGGTGAGTCGCTCACCGACTTCCG	This study
Cdelupi	TATAGATATCCGAGGCGGAGCGTCGAGAGCGCTAGTC	This study
Cdelido	TATATCTAGACGTGCGAGAAGCTCGTCGACGGACTCGTCC	This study
Cdeldoi	TATAGATATCCGAAGTGAAGAATCAGGAGACGGCATTGC	This study

















**Table 2.**

<b>strain</b>	<b>icrRNA plasmid</b>	<b>reduction in transformation rate by factor</b>
$\Delta C$	pTA409-telecrRNA (low copy)	0.01
$\Delta C$	pTA232-telecrRNA (high copy)	0.01
$\Delta cas6b$	pTA232-telecrRNA (high copy)	0.0006

**Table 3.**

position changed	schematic drawing of icrRNA variants	reduction in transformation rate by factor
wild type		0.001
nucleotide -8 mutated: G -> A (variant 4)		0.005
nucleotide -8 mutated: G -> U (variant 5)		0.003
nucleotide -8 mutated: G -> C (variant 6)		0.006
nucleotide -1 mutated: C -> U (variant 8)		0.0009
nucleotide -1 mutated: C -> G (variant 9)		no reduction: no interference
nucleotide -1 mutated: C -> A (variant 10)		0.006
3 nucleotide internal deletion (variant 7)		no reduction: no interference
nucleotide -8 deleted (variant 17)		0.0003
nucleotides -8 and -7 deleted (variant 18)		no reduction: no interference
5' handle completely deleted (variant 3)		no reduction: no interference

**Table 4.**

position changed	schematic drawing of icrRNA variants	reduction in transformation rate by factor
wild type		0.001
mutation in loop: G -> U (variant 11)		0.003
mutation in loop: G -> C (variant 12)		0.005
deletion of nucleotides 8-11 (variant 1)		0.008
deletion of nucleotides 1-11 (variant 2)		0.002
5 nucleotide deletion from 3' end (variant 13)		0.01
10 nucleotide deletion from 3' end (variant 14)		0.008
15 nucleotide deletion from 3' end (variant 15)		0.004
20 nucleotide deletion from 3' end (variant 16)		0.002
1 nucleotide from 3' end (variant 20)		0.001
nucleotide 1 mutated G->C (variant 21)		0.002
nucleotide 1 mutated G->A (variant 22)		0.005
nucleotide 1 mutated G->U (variant 23)		0.008
no 3' handle (variant 19)		0.001

**Figure 1A.**




Figure 1B.




Figure 1C.




Figure 2A.





Figure 2B.







**Figure 4**

